Glaukos (GKOS) Cash from Investing Activities (2014 - 2026)
Glaukos' (GKOS) quarterly Cash from Investing Activities came in at $10.5 million in Q1 2026, up 128.43% year-on-year from $4.6 million in Q1 2025, and up 166.1% on a QoQ basis from -$15.9 million in Q4 2025.
Glaukos (GKOS) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Glaukos (GKOS) has 13 years of Cash from Investing Activities data on file, last reported at $10.5 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 128.43% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was -$30.2 million, a 174.9% decrease from a year earlier, with the FY2025 full-year figure at -$77.6 million, down 262.27% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $10.5 million, up from -$15.9 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for GKOS reached as high as $34.9 million in Q2 2024 and fell as low as -$36.9 million in Q1 2025.
- Historically, Cash from Investing Activities has averaged $2.3 million across 5 years, with a median of $9.6 million in 2022.
- Across the five-year window, Cash from Investing Activities surged 573.45% in 2022 and sank 234.81% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at $16.7 million in 2022, then sank by 177.58% to -$12.9 million in 2023, then surged by 191.22% to $11.8 million in 2024, then sank by 234.81% to -$15.9 million in 2025, then jumped by 166.1% to $10.5 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $10.5 million in Q1 2026, -$15.9 million in Q4 2025, and -$4.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.95 Bn | 176.66 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.83 Bn | 125.95 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.81 Bn | 99.59 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.39 Bn | 66.94 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.28 Bn | 44.60 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.39 Bn | 27.27 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 28.30 Bn | 26.01 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Glaukos | 8.77 Bn | 8.67 Bn | 117.23 Mn | 10.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.50 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | -15.89 Mn |
| Dec 31, 2025 | -15.89 Mn |
| Sep 30, 2025 | -3.99 Mn |
| Sep 30, 2025 | -3.99 Mn |
| Jun 30, 2025 | -20.78 Mn |
| Jun 30, 2025 | -20.78 Mn |
| Mar 31, 2025 | -36.95 Mn |
| Mar 31, 2025 | -36.95 Mn |
| Dec 31, 2024 | 11.79 Mn |
| Dec 31, 2024 | 11.79 Mn |
| Sep 30, 2024 | 30.56 Mn |
| Sep 30, 2024 | 30.56 Mn |
| Jun 30, 2024 | 34.86 Mn |
| Jun 30, 2024 | 34.86 Mn |
| Mar 31, 2024 | -29.38 Mn |
| Mar 31, 2024 | -29.38 Mn |
| Dec 31, 2023 | -12.92 Mn |
| Dec 31, 2023 | -12.92 Mn |